Developing new options for Cystic Fibrosis lung infections

Disrupting the biofilms that protect chronic lung bacterial infections

Cystic Fibrosis affects 1 in 3,500 births with approximately 70,000 patients worldwide and 31,000 in the USA alone.

Patients develop a thick sticky mucus in their lungs, which are susceptible to infection and which over time results in inflammation and lung function decline.

Respirion is developing a novel inhaled treatment for Cystic Fibrosis patients that combines a widely used antibiotic with a biofilm disrupting agent. This treatment has been shown in an initial patient study to significantly improve bacterial clearance and improve lung function.

Clinical Trial Now Open

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection.

Learn more on the website.

Learn more

Latest News


MEDIA RELEASE | Respirion offers hope for people living with cystic fibrosis

Highlights: An international clinical trial is underway on a Western Australian-developed inhaled antibiotic combination for people with cystic fibrosis A preliminary clinical study had shown…


Respirion’s technology was featured on Channel 9 News on Sunday 12 May 2024.  17-year-old Sienna O’Reilly, who has lived with Cystic Fibrosis her whole life,…
Company News

MEDIA RELEASE | Respirion Selected For Early-Stage Translation and Commercialisation Support (ESTAC) grant.

CUREator by Brandon BioCatalyst has announced the deployment of $7.21 million in funding to support eight biotech companies across its Clinical and Preclinical streams thanks…